Quick Answer
Oncotelic Therapeutics, Inc. reported Total Revenue of $70.0 thousand for the year ending 2023.
- Oncotelic Therapeutics, Inc. showed a decrease of -96.0% in Total Revenue from 2020 to 2023.
- This data is from Oncotelic Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on April 15, 2025.
- XBRL data for this metric is available from 2020 to 2023 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $340.9 thousand | Q2 2020: $1.40 million | Q3 2023: $70.0 thousand.
- Over the full 3 years of available data (2020 to 2023), Oncotelic Therapeutics, Inc.'s Total Revenue has declined by 96.0%.
- Historical annual values: Fiscal year 2023: $70.0 thousand | Fiscal year 2020: $1.74 million | Fiscal year 2020: $1.74 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: